Anticorps Recombinant de lapin anti-STAMBP

STAMBP Recombinant Antibody for WB, IF/ICC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

251545B3

N° de cat : 86601-3-PBS

Synonymes

AMSH, EC:3.4.19.-, Endosome-associated ubiquitin isopeptidase, STAM binding protein, STAM-binding protein



Informations sur le produit

86601-3-PBS cible STAMBP dans les applications de WB, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène STAMBP Protéine recombinante Ag1895
Nom complet STAM binding protein
Masse moléculaire calculée 48 kDa
Poids moléculaire observé 48 kDa
Numéro d’acquisition GenBankBC007682
Symbole du gène STAMBP
Identification du gène (NCBI) 10617
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

STAM-binding protein (STAMBP) is also named AMSH. STAMBP, a member of the Jab1/MPN metalloenzyme family of deubiquitinating enzymes (DUBs), specifically cleaves K63-linked polyubiquitination chains from substrates (PMID: 15314065, PMID: 26601948). STAMBP is implicated in the endosome-lysosome pathway and shuttles ubiquitinated substrate proteins to lysosomes for degradation (PMID: 10383417, PMID: 24151880). STAMBP regulates protein degradation by binding to the ESCRT-0 protein STAM and the charged multivesicular body proteins of the ESCRT-III complex (PMID: 20159979). STAMBP is implicated in the inflammatory response by promoting the deubiquitination and stabilization of NALP7 and increasing the activity of inflammasomes (PMID: 28492230). STAMBP expression was increased in the cytoplasm of tumor cells from LUAD patients. STAMBP overexpression promoted cell migration and invasion, whereas STAMBP knockdown attenuated these processes in LUAD cells after epidermal growth factor treatment (PMID: 3410245).

{{ptg:RelatedPrimaryAntibodies}}